MDMA

Dose and pattern of use are the primary determinants of MDMA detection. MDMA has a plasma half-life of roughly 7–9 hours in typical adults, with non-linear pharmacokinetics that disproportionately extend the apparent half-life at higher doses because metabolism via CYP2D6 saturates. A single 80–120 mg recreational dose typically produces urinary detection for 1–3 days; doses in the 150–250 mg range encountered in heavier users push detection toward the upper bound of the published window. The festival and club pattern of repeat-dosing across an evening or across consecutive nights extends detection because each successive dose layers onto incomplete clearance of the previous one, and the active metabolite MDA accumulates with repeated exposure. Programs evaluating donors after a festival weekend should expect detection windows at the longer end of the published range and should not interpret a positive several days after the event as evidence of subsequent use.

Metabolism proceeds primarily through hepatic CYP2D6, with smaller contributions from CYP3A4, CYP1A2, and CYP2B6, followed by O-methylation and conjugation prior to renal excretion. CYP2D6 is among the most polymorphic of the cytochromes, and known poor metabolizers — disproportionately represented among individuals of European and East Asian ancestry — show meaningfully prolonged MDMA half-life and extended detection windows. Co-administration of CYP2D6 inhibitors (paroxetine, fluoxetine, bupropion, ritonavir, quinidine, terbinafine) similarly extends detection. Some of these interactions are also pharmacodynamically dangerous because they elevate plasma MDMA concentrations and increase the risk of serotonin toxicity and hyperthermia. Hepatic impairment from cirrhosis or hepatitis prolongs clearance; significant impairment is uncommon in the typical MDMA-using demographic but matters in MAT and rehab populations with mixed substance histories.

Urinary pH has a measurable effect on MDMA excretion. As a weak base with a pKa near 9.9, MDMA is excreted more rapidly in acidic urine and more slowly in alkaline urine, which can shift the detectable window by 12–24 hours in either direction. Hydration status, physical activity, and dietary composition all influence urine pH and therefore detection. Renal function is also relevant: significant renal impairment extends detection of both parent MDMA and the MDA metabolite. Age and body composition contribute smaller effects; MDMA is moderately lipophilic but does not exhibit the deep adipose sequestration seen with THC, so BMI is not a dominant variable. Pediatric and geriatric pharmacokinetics differ from healthy-adult parameters, which is operationally relevant for emergency departments evaluating non-adult or older-adult MDMA exposures.

Specimen matrix selection materially changes what the test reports. Oral fluid favors detection of parent MDMA over metabolites and has a shorter window than urine, but it supports observed collection without the privacy and chain-of-custody complications of witnessed urine collection — a meaningful operational advantage for reasonable-suspicion and post-accident testing. Hair captures cumulative exposure across roughly the prior 90 days and is the matrix of choice for retrospective pattern analysis but cannot resolve a single exposure within that window. Blood is appropriate for impairment investigations because it correlates more closely with current effect than urine does, but it has the shortest window of any matrix and requires phlebotomy. Programs should select the matrix that matches the operational question being asked — random workplace screening, post-accident impairment evaluation, treatment-program compliance monitoring, or retrospective pattern documentation.

MDMA is included in the SAMHSA Mandatory Guidelines panel within the amphetamines analyte class. The federal screening cutoff for amphetamines (including MDMA) is 500 ng/mL, and the confirmation cutoff by GC-MS or LC-MS/MS is 250 ng/mL for amphetamine, methamphetamine, MDMA, and MDA. This means a standard SAMHSA-style 5-panel test that includes the amphetamines analyte will flag a donor exposed to MDMA at federally specified thresholds, with MDMA and MDA identified specifically at the confirmation stage. DOT-regulated programs (49 CFR Part 40) adopt the SAMHSA cutoffs by reference, so commercial-driver, transit, aviation, rail, pipeline, and maritime testing all use the same 500/250 ng/mL thresholds. A presumptive positive at the screening stage is, operationally, a result the collector forwards to the laboratory and the MRO — it is not a verified positive and cannot be communicated to the employer as such until confirmation and MRO review are complete.

Magenta's multi-panel cups and dip cards include either a combined amphetamines/methamphetamine analyte that captures MDMA at SAMHSA cutoffs or, on higher-panel devices, a discrete MDMA strip that allows the screening result to differentiate MDMA-class exposure from amphetamine- and methamphetamine-class exposure at the immunoassay stage. Both approaches produce SAMHSA-aligned screening results; the discrete strip simplifies Medical Review Officer follow-up by indicating the likely class before confirmation results return. The gap between immunoassay screening and definitive identification by GC-MS or LC-MS/MS is the single most important concept for program administrators to communicate to supervisors and HR partners — immunoassay produces a presumptive class-level result, mass spectrometry produces an analyte-specific quantitative result, and only the latter, after MRO review against the donor's prescription history, supports adverse action.

Programs operating outside the federal SAMHSA framework — clinical addiction treatment, criminal-justice diversion, sober living, occupational health for non-regulated employers, and similar settings — sometimes select non-SAMHSA cutoffs. Lower screening cutoffs (300 ng/mL or 250 ng/mL) are available from some manufacturers and extend the detection window at the cost of increased false-positive rates and increased MRO workload. CLIA-waived devices like Magenta's cups and dip cards make these non-regulated cutoffs operationally accessible without sending every specimen to a reference laboratory for primary screening. Programs should make this trade-off deliberately and document the cutoff selected so that result interpretation is consistent across the program, and they should retain the option to send presumptive positives to a SAMHSA-certified laboratory for definitive confirmation regardless of whether the screening cutoff was federally specified.

Lateral-flow immunoassays detect MDMA either through a combined amphetamine-class antibody that cross-reacts with MDMA at the screening cutoff or through an MDMA-specific antibody on devices that separate the analytes. Mechanistically, the device strip carries an immobilized drug-protein conjugate on the test line and a labeled antibody in the conjugate pad; when the specimen contains analyte at or above the cutoff, free analyte saturates the antibody, blocking it from binding the conjugate line — which is why a visible test line indicates negative and an absent test line indicates presumptive positive. The combined-class approach mirrors how SAMHSA defines the amphetamines panel and is the most common configuration on workplace-style cups and dip cards. Result interpretation follows the standard rule used across Magenta devices: absent test line indicates a presumptive positive at the device cutoff, visible test line indicates negative, and absent control line invalidates the result and requires recollection.

Cross-reactivity within the amphetamines class is by design — methamphetamine, amphetamine, MDMA, and MDA all produce positive screens at SAMHSA cutoffs on a class-based amphetamines analyte. This is the source of the well-known limitation that the screening result alone cannot tell a program whether the donor used methamphetamine, prescription Adderall, MDMA, or another class member. Confirmation testing by LC-MS/MS resolves the specific analyte present and quantifies it relative to the confirmation cutoff. Devices with a discrete MDMA strip mitigate but do not eliminate this differentiation issue at the screening stage. The cross-reactivity table in any device package insert lists specific compounds tested and the concentrations at which they produce a positive — for MDMA-specific strips this typically includes MDMA, MDA, MDEA, and certain ring-substituted analogs with declining cross-reactivity for the parent amphetamine and methamphetamine.

False positives outside the amphetamines class are uncommon for well-designed MDMA assays, but several substances have been reported to produce cross-reactivity at supraphysiologic concentrations: bupropion and its hydroxybupropion metabolite, ranitidine, ephedrine and pseudoephedrine (older devices), labetalol, ritodrine, trazodone, and certain selegiline metabolites that include amphetamine and methamphetamine. Modern device chemistries have substantially reduced these issues, but Medical Review Officer review of any confirmed positive against the donor's prescription and over-the-counter exposure history remains the standard of care before any adverse action. Invalid or adulterated specimens are flagged by specimen integrity panels and may reflect dilute samples, oxidant additives such as nitrite or pyridinium chlorochromate, or substituted synthetic urines; collectors trained to observe specimen temperature within four minutes of collection (90–100°F) catch the most common substitution attempts at the point of collection.

Confirmation testing is essential for any MDMA-class positive that will inform employment, treatment, or legal decisions. SAMHSA-certified laboratories perform GC-MS or LC-MS/MS confirmation at 250 ng/mL and report quantitative results for MDMA, MDA, amphetamine, and methamphetamine separately. The presence of MDA without parent MDMA can indicate either MDMA exposure with rapid metabolism or direct MDA exposure (MDA is itself a Schedule I substance). Pattern analysis of MDMA:MDA ratios can sometimes support inferences about timing and dose pattern. Chain-of-custody documentation accompanies the specimen from collection through laboratory analysis and MRO review; any break in custody — unsealed bottles, missing collector signatures, mismatched specimen IDs — can render an otherwise positive result unusable for adverse action and is a primary source of preventable program failure.

Specimen integrity testing accompanies MDMA screens as it does all other analytes. Creatinine, specific gravity, pH, and oxidant adulterant panels should be evaluated before any positive result is finalized. Festival and club populations may present with dehydration that affects creatinine and specific gravity; programs should follow their standard repeat-collection protocol rather than interpreting these findings as evidence of adulteration without supporting data. Collection mode also matters: unobserved collection is the default for routine workplace random testing, while observed collection is appropriate for reasonable-suspicion, post-accident, return-to-duty, and follow-up testing under DOT and many non-DOT programs — and observed collection is the operational answer when prior specimens have triggered integrity flags.